COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
12/08/2025
KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE [...]
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
12/08/2025
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions [...]
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
12/08/2025
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions [...]
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
12/08/2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes [...]
Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025
12/08/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports solid financial results for the first half of 2025 and confirms its outlook for full year 2025 Financial results for [...]
iPETcertum™ by Claritas, Developed with Cutting-Edge Technology for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives FDA Clearance
12/08/2025
LONDON and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art signal processing, quantification and AI technologies [...]
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités
12/08/2025
Chiffre d’affaires de 97,6 millions d’euros contre 70,8 millions d’euros au premier semestre 2024 Trésorerie de 161,3 millions d’euros à fin juin 2025 Poursuite des avancées cliniques et réglementaires Confirmation des [...]
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
12/08/2025
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024 Cash and cash equivalents of €161.3 million at end of June 2025 Further clinical and regulatory progress 2025 financial outlook [...]
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
12/08/2025
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support global Sandoz [...]
Phonak unveils Virto R Infinio: the compact rechargeable hearing aid designed for today's active lifestyle
12/08/2025
STÄFA, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Phonak , a global leader in hearing care solutions is excited to introduce the Virto R Infinio, its most compact rechargeable custom in-the-ear (ITE) hearing aid [...]
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
12/08/2025
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated with ianalumab also [...]
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
11/08/2025
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in [...]
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to [...]
Standard BioTools Reports Second Quarter 2025 Financial Results
11/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. [...]
Harrow Announces Second-Quarter 2025 Financial Results
11/08/2025
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million [...]
Xenon Reports Second Quarter 2025 Financial Results & Business Update
11/08/2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently [...]
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
11/08/2025
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO [...]
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support [...]
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
11/08/2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo [...]

Pages